BioCentury
ARTICLE | Clinical News

Epizyme reports Phase II data for tazemetostat in lymphoma

June 16, 2017 9:32 PM UTC

Epizyme Inc. (NASDAQ:EPZM) reported interim data from 203 evaluable patients with relapsed or refractory follicular lymphoma or diffuse large B cell lymphoma (DLBCL) in the Phase II portion of a Phase I/II trial showing that twice-daily 800 mg oral tazemetostat (EPZ-6438, EPZ-6438) led to an objective response rate (ORR) of 92%, including 1 complete response and 11 partial responses, in 13 follicular lymphoma patients with enhancer of zeste homolog 2 (EZH2) activating mutations. In 54 follicular lymphoma patients with wild-type EZH2, tazemetostat led to an ORR of 26%, including 3 complete responses and 11 partial responses.

In 17 DLBCL patients with EZH2 activating mutations, tazemetostat led to an ORR of 29%, including 5 partial responses. In 119 DLBCL patients with wild-type EZH2, tazemetostat led to an ORR of 15%, including 10 complete responses and 8 partial responses. Data were presented at the International Conference on Malignant Lymphoma in Lugano...

BCIQ Company Profiles

Eisai Co. Ltd.

Epizyme Inc.